Subject(s)
Anemia/drug therapy , Erythropoietin/administration & dosage , Myelodysplastic Syndromes/complications , Aged , Aged, 80 and over , Cytogenetic Analysis , Erythropoietin/toxicity , Female , Hemoglobins , Humans , Male , Middle Aged , Myelodysplastic Syndromes/drug therapy , Recombinant Proteins , Treatment OutcomeABSTRACT
We report 6 pregnancies in 5 females with low-risk myelodysplastic syndromes (MDS) (median age at diagnosis 28 years, range 26-29) observed in the last 15 years. In 2 cases pregnancy was concomitant to the diagnosis of MDS, in the remaining 4 cases the intervals from diagnosis were 2, 3, 4 and 9 years, respectively. One patient had a foetal growth retardation corrected with steroid treatment while the remaining 5 pregnancies were uneventful. After a median time from delivery of 104 months (range 18-187) none of the patients developed acute myeloid leukemia (AML) and all are alive in stable disease. In conclusion, selected females with low-risk MDS could not be discouraged to have full term pregnancies.
Subject(s)
Myelodysplastic Syndromes/diagnosis , Pregnancy Complications, Hematologic/diagnosis , Adult , Animals , Female , Humans , Pregnancy , Pregnancy OutcomeABSTRACT
We report on a double-blind, placebo-controlled study of carbamazepine (CBZ) treatment for cocaine dependence. A previously reported uncontrolled study found CBZ to be a beneficial pharmacotherapy for cocaine dependence. Statistical analyses were performed on data from 82 subjects who were randomized to 10 weeks' treatment with either CBZ, titrated to 4-12 micrograms/ml, (n = 37) or placebo (n = 45). The two treatment groups did not differ for primary outcome measures of retention time in treatment, urine samples positive for cocaine metabolite, subject reported desire for cocaine or for subject reported side-effects. CBZ was not an effective treatment in this study.
